Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

PHILLIPSBURG, N.J., Jan. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of primary brain cancer and carries a very poor prognosis with current therapy. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII that can be expressed by GBM.

In the ACTIVATE Phase 2a study, GBM patients treated with CDX-110 showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. GBM that recurred after treatment with CDX-110 consistently lost EGFRvIII expression with its aggressive growth signal. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. Preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase 2/3 randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, and safety of the addition of CDX-110 vaccine to standard of care, versus standard of care alone. Celldex recently announced that CDX-110 has also been granted Orphan Drug Status by the FDA. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq:

SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... 23, 2014  Researchers from the North American Menopause ... elevates calcium levels too high, 1 putting women ... Women close to menopause are commonly told ... prevent diseases such as osteoporosis, to which they are ... determine how much calcium they typically get through their ...
(Date:7/23/2014)... 23, 2014  Mevesi Inc. would like to ... integration provides pharmacies with the ability to send ... patients. Mevesi,s solutions provide an ... to define target marketing campaigns. This coupled with ... within the Digital Marketing, Population Management, and Pharmacy ...
(Date:7/23/2014)... 2014 Global healthcare company GSK ... currency headwinds, increased price competition and supply disruptions to ... Witty points out that the company is very much ... to be confident about long-term prospects as well as ... CFO Simon Dingemans adds that the ...
Breaking Medicine Technology:Women Taking Too Much Calcium Create Health Risk 2Mevesi Enhances Solutions with Variable Print Media Capabilities! 2
... , , Trial taking place ... Ky., July 24 Michael (Mike) Jones has become the world,s first ... infusion on July 17 marks the world,s first phase-one FDA-approved clinical trial ... is being conducted by a team of University of Louisville physicians at ...
... , WISCONSIN RAPIDS, Wis., July 23 ... Riverview became the first medical facility in the world to ... within Riverview Hospital, Wisconsin Rapids, the UW Cancer Center Riverview ... FDA-cleared Axxent(R) Electronic Brachytherapy System from Xoft, Inc. Electronic Brachytherapy, ...
Cached Medicine Technology:World's First Cardiac Adult Stem Cell Patient Receives Infusion 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 2First Skin Cancer Patients Treated With Electronic Brachytherapy (eBx) At University of Wisconsin Riverview Cancer Center 3
(Date:7/23/2014)... 2014 (HealthDay News) --,Jealousy may not be the sole ... get downright possessive when it comes to the love ... toward what was actually a stuffed dog, the real ... the stuffed dog aside, report researchers from the University ... only surfaced when owners were attending to the stuffed ...
(Date:7/23/2014)... effort to catalog the molecular causes of stomach ... have identified four subtypes of tumors based on ... the new classification promises to advance clinical research ... killer worldwide. , In a report in ... Research Network said they analyzed 295 samples of ...
(Date:7/23/2014)... 2014 Texas Physical Therapy Specialists (TexPTS) ... their Westlake, Westgate, Liberty Hill, Parmer, Balcones, and Georgetown ... of Orthopaedic Certified Specialist (OCS) or ... PT, DPT, OCS, Tony Lauretta, PT, DPT, OCS, Jason ... Joseph Leech, PT, DPT, OCS, and Mary Grimberg, PT, ...
(Date:7/23/2014)... A therapy combining salmon fibrin injections into the spinal ... brain restored voluntary motor function impaired by spinal cord ... found. , In a study on rodents, Gail Lewandowski ... the developmental clock in a molecular pathway critical to ... a scaffold so that neuronal axons at the injury ...
(Date:7/23/2014)... North American market was valued at $985.4 million in 2012. ... 10.79%, to reach $1,801.1 million by 2018. Organobromines is the ... Bromine Market report defines and segments the bromine market in ... the TOC of the North American Bromine Market report, to ... provides a glimpse of the segmentation in the North America ...
Breaking Medicine News(10 mins):Health News:Dogs Can Get Jealous, Too 2Health News:New view of stomach cancer could hasten better therapies 2Health News:New view of stomach cancer could hasten better therapies 3Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 2Health News:Texas Physical Therapy Specialists Congratulates New Board Certified Specialists 3Health News:Gene inhibitor, salmon fibrin restore function lost in spinal cord injury 2Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 2Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 3Health News:North America Bromine Market is Expected to Reach $1801.1 million in 2018 - New Report by MicroMarket Monitor 4
... ... drug efficacy and reducing side effects , ... Santa Barbara, Calif. (Vocus) April 8, 2010 -- Researchers have ... penetrate deeply into tumor tissue. The peptide has been shown to substantially increase treatment ...
... effective as blood thinner, study finds , THURSDAY, April 8 ... works as well as medication -- and is safer -- ... device is as useful as blood thinners for the reduction ... safety," said study co-author Dr. Douglas E. Padgett, chief of ...
... have resulted in extended and repeated combat-related deployments of U.S. ... problems, both physical and psychological, many bring back with them, ... home can have issues as well. The ... quickly adjust to altered family roles and the stress of ...
... can take in the waiting room may lead to ... News) -- A researcher has developed a brief ... suffering from the early memory and reasoning problems that ... the journal Alzheimer Disease and Associated Disorders , ...
... under Singapore,s Agency for Science, Technology and Research (A*STAR), ... (SIgN), are collaborating with Italy,s Siena Biotech S.p.A. to ... potentially help millions of cancer and bone loss patients ... collaboration A*STAR has with research centres and universities in ...
... others interested in the chemical sciences are invited to ... Society (ACS) Webinars, focusing on Professional Growth and Development. ... p.m. Eastern Time, the free webinar will feature Martin ... years of experience working on immigration visas for scientists, ...
Cached Medicine News:Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 2Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 3Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 4Health News:Research Reveals Cancer Drug Effectiveness Substantially Advanced 5Health News: Compression Device May Outperform Meds After Hip Surgery 2Health News:Children of combat-deployed parents show increased worries, even after parent returns 2Health News:Simple Memory Test May Detect Early Alzheimer's 2Health News:Exploring the 'Davids and Goliaths' of therapeutic molecules 2Health News:Exploring the 'Davids and Goliaths' of therapeutic molecules 3Health News:ACS Webinar focuses on immigration law for scientific professionals 2
300 L, Bulk Recommended for 250 and 300 L pipettes. Can also be used with 20, 25, 50, 100 and 200 L pipette...
Its MicroPoint design and reference marks at 10, 50 and 100 L ensure accurate performance with a variety of multi-channel and single-channel pipettors....
... its wide orifice tip, the Finntip Wide ... suspensions and macromolecules like genomic DNA. This ... cell fragmentation. It is excellent for use ... model, the inside diameter of the orifice ...
MBP's equivalent to the "Universal Yellow" tip, this 200 ul tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
Medicine Products: